George P. Canellos, MD
William Rosenberg Professor of Medicine, Harvard Medical School
Office phone: 617-632-3470
Preferred contact method: appointment phone
View Physician Profile
Lymphoma, Chronic lymphocytic leukemia
Area of ResearchDiagnosis and Treatment of Lymphoma
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
BiographyDr. Canellos received his MD in 1960 from Columbia University. After internship and residency at Massachusetts General Hospital, he was a clinical associate at the National Cancer Institute and a research fellow at the Royal Postgraduate Medical School in London. From 1975 to 1995, he served as chief of DFCI's Division of Medical Oncology and as medical director for network development for Dana-Farber/Partners CancerCare. He is currently a senior physician at DFCI and Brigham and Women's Hospital. He is the former Editor-in-Chief of the Journal of Clinical Oncology and President of the American Society of Clinical Oncology.
- Karl Musshof Award from the 7th International Hodgkin Lymphoma Symposium, 2007
- Statesman Award, American Society of Clinical Oncology, 2007
- Frank S. Moran Clinical Research Award, University of Michigan Cancer Center, 2006
- San Salvatore Foundation Award at the 9th International Conference on Lymphoma., 2005
- Ellis Island Foundation Medal of Honor, 2004
- Key to the Cure Award, The Cure for Lymphoma Foundation, 1999
- Honorary Doctor of Science, University of Athens, Greece, 1997
- Distinguished Service Award for Scientific Achievement, American Society of Clinical Oncology, 1996
- Fellowship, Royal College of Physicians London and Edinburgh, 1991
ResearchDiagnosis and Treatment of Lymphoma
Our research interests span a broad area of cytotoxic chemotherapeutic agents as well as biological agents for the treatment of malignant diseases.
As former chair of the Lymphoma Committee of the Cancer and Leukemia Group B, a national cooperative trials group, Dr. Canellos initiated clinical trials in close collaboration with other groups. These trials search for answers concerning many issues, such as:
-The optimal tolerable chemotherapy regimen for the treatment of advanced Hodgkin's disease and non-Hodgkin's lymphoma
- The integration of antibody therapy with cytotoxic agents for the treatment of these diseases
- The role of early high-dose autologous transplantation in the management of poor-prognosis patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
In addition, new initiatives are under way in the use of radioimmunotherapy combined with cytotoxic therapy and the development of new agents for the treatment of lymphoma. We are exploring diagnostics to define the presence of residual disease using positron emission tomographic (PET) scans and a comparison with gallium/single photon emission computed tomography. SPECT was pioneered at DFCI for the treatment of lymphoma, and has helped to identify those patients at particularly high risk following cytotoxic treatment.He continues to be the "senior statesman" in the lymphoma group.